| Oct 22 |
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
|
| Oct 11 |
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
|
| Oct 10 |
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
|
| Oct 9 |
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
|
| Oct 9 |
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
|
| Oct 8 |
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
|
| Sep 24 |
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
|
| Sep 10 |
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
|
| Aug 22 |
Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease
|
| Jul 12 |
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
|
